Sign inSubscribe

target directory

anemia in dialysis dependent chronic kidney disease dd ckd clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT03140722
Source recordAI-normalized

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

The trial evaluated vadadustat, an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor, against epoetin alfa for treating anemia in patients with DD-CKD who are hyporesponsive to erythropoiesis stimulating agents. The study was terminated due to a revised study design after enrolling only 2 participants.

AI analysis

Indication: Anemia

Modality: small molecule

Target: Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Sponsor: Akebia Therapeutics

Source URL: ClinicalTrials.gov

Source updated: Feb 21, 2021

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

View original source fields

Condition raw: Anemia

Condition normalized: Anemia

Modality raw: Anemia

Modality normalized: small molecule

Target raw: Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Target normalized: Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Open report